Rivastigmine Transdermal System Patch, Extended Release
Product Images NDC 63629-2065

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Rivastigmine Transdermal System (NDC 63629-2065). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636292065)

This is a description of a pharmaceutical product called Rivastigmine Transdermal System. It comes in a pack of 30 systems, with each system containing 9mg of Rivastigmine, providing a 4.6mg dosage every 24 hours. The product should be stored at a temperature between 15°C to 30°C, and wearing more than one patch at a time is prohibited. Users should apply the patch to clean and dry skin once a day and replace it every 24 hours without cutting it. The product should be kept out of reach from children as it is only for Transdermal Use Only. The National Drug Code identification number is 63629-2065-1.*

FDA Label Image

Chemical Structure (Rivastigmine 01)

FDA Label Image

Figure 1 (Rivastigmine 02)

FDA Label Image

Figure 2 (Rivastigmine 03)

This is a table that shows the concentration (in ng/mL) of Rivastigmine, a medication used for dementia, in three different dosages (13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours) taken by a total of 63 patients. There are 19 patients in the first group, 22 in the second group, and another 22 in the third group.*

FDA Label Image

Figure 3 (Rivastigmine 04)

This is a table representation of the ADAS-Cog test rating. It shows the least square means with standard error mean (SEM) and the change from baseline, as well as the clinical improvement and decline at 16 weeks during the treatment. The table also displays the dosages of two different medications, Gapstles 6 mg BID, and 95 mgr24 hours, along with a placebo.*

FDA Label Image

Figure 4 (Rivastigmine 05)

FDA Label Image

Figure 5 (Rivastigmine 06)

FDA Label Image

Figure 6 (Rivastigmine 07)

Not available.*

FDA Label Image

Figure 7 (Rivastigmine 08)

This appears to be a statistical analysis comparing the improvement from treatment with two different transdermal systems using rivastigmine. The data includes LS means and standard errors for both treatments at various time intervals (8, 16, and 24 weeks) and indicates statistical significance at a level of 0.05.*

FDA Label Image

Figure 8 (Rivastigmine 09)

This is a description of clinical trial results for a medication called Rivastigmine Transdermal System. The trial lasted for 16 weeks and involved patients with a decline in cognitive function. Two different doses of the medication were tested and measured in least squares means (LS means) with standard errors. The results show statistical significance at a level of 0.05 for one of the doses.*

FDA Label Image

Figure A (Rivastigmine 10)

FDA Label Image

Figure B (Rivastigmine 11)

This appears to be a list of body parts with no further context or information. It is not possible to generate a useful description with this information.*

FDA Label Image

Figure C (Rivastigmine 12)

FDA Label Image

Figure D (Rivastigmine 13)

FDA Label Image

Figure E (Rivastigmine 14)

FDA Label Image

Figure F (Rivastigmine 15)

FDA Label Image

Figure G (Rivastigmine 16)

FDA Label Image

Figure H (Rivastigmine 17)

This text appears to be instructions for disposing of a folded patch. It is recommended to fold the sticky sides together and place the patch in the trash. Additionally, it suggests keeping the folded patch away from children and pets.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.